麻黃鹼 (Chinese Wikipedia)

Analysis of information sources in references of the Wikipedia article "麻黃鹼" in Chinese language version.

refsWebsite

Global rank Chinese rank

34web.archive.org

1^st place

25doi.org

2^nd place

23^rd place

25nih.gov

4^th place

5^th place

7semanticscholar.org

11^th place

332^nd place

6books.google.com

3^rd place

8^th place

2medicines.org.uk

3,823^rd place

3,456^th place

2drugs.com

399^th place

208^th place

2worldcat.org

5^th place

12^th place

2wada-ama.org

9,542^nd place

9,880^th place

1federalregister.gov

2,474^th place

3,822^nd place

1drugbank.com

low place

1in.gov.br

3,151^st place

low place

1handle.net

102^nd place

492^nd place

1mhmedical.com

6,846^th place

low place

1neurology.org

9,919^th place

4,563^rd place

1zenodo.org

621^st place

1,608^th place

1fda.gov

447^th place

581^st place

1merckmanuals.com

3,097^th place

1,801^st place

1incb.org

low place

5,336^th place

1hc-sc.gc.ca

low place

1justice.gc.ca

2,540^th place

3,732^nd place

1ephedrinehydrochloride.com

low place

1drugfreesport.com

low place

1doh.gov.za

low place

1buzer.de

3,974^th place

low place

1chinadialogue.net

low place

1sciencedirect.com

149^th place

292^nd place

1harvard.edu

18^th place

57^th place

books.google.com

Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation : a reference guide to fetal and neonatal risk 9th. Philadelphia: Lippincott Williams & Wilkins. 2011: 495. ISBN 9781608317080. （原始内容存档于2017-09-08）.
Soni MG, Shelke K, Amin R, Talati. A Lessons from the Use of Ephedra Products as a Dietary Supplement. Bagchi D, Preuss HG (编). Obesity epidemiology, pathophysiology, and prevention 2nd. Boca Raton, Florida: CRC Press. 2013: 692. ISBN 9781439854266. （原始内容存档于2017-09-08）.
Fischer J, Ganellin CR. Analogue-based Drug Discovery. John Wiley & Sons. 2006: 541. ISBN 9783527607495.
Buckey Jr JC. Space Physiology. Oxford University Press. 2006: 201. ISBN 978-0-1997-4790-0.
Sanford CA, Jong EC. The Travel and Tropical Medicine Manual E-Book. Elsevier Health Sciences. 2008: 139. ISBN 978-1437710694.
Bray GA, Bouchard C. Handbook of obesity. CRC Press. 2004: 494–496. ISBN 978-0-8247-4773-2. （原始内容存档于2014-06-26）.

buzer.de

Verordnung zur Neuordnung der Verschreibungspflicht von Arzneimitteln (AMVVNV). 互联网档案馆的存檔，存档日期2014-05-17. V. v. 21. Dezember 2005 BGBl. I S. 3632; Geltung ab 1. Januar 2006.

chinadialogue.net

Long C. Chinese medicine's great waste of resources. 2007-01-15 [2016-05-09]. （原始内容存档于2016-05-30）.

doh.gov.za

Rescheduling of Medicines that Contain Ephedrine. [2009-04-18]. （原始内容存档于2009-06-28）.

doi.org

Volpp M, Holzgrabe U. Determination of plasma protein binding for sympathomimetic drugs by means of ultrafiltration. Eur J Pharm Sci. January 2019, 127: 175–184. PMID 30391401. doi:10.1016/j.ejps.2018.10.027.
Schmidt S. Lang-etablierte Arzneistoffe genauer unter die Lupe genommen: Enantioselektive Proteinbindung und Stabilitätsstudien [A closer look at long-established drugs: enantioselective protein binding and stability studies] (学位论文). Universität Würzburg. 2023. doi:10.25972/opus-34594 （德语）.
Gad MZ, Azab SS, Khattab AR, Farag MA. Over a century since ephedrine discovery: an updated revisit to its pharmacological aspects, functionality and toxicity in comparison to its herbal extracts. Food Funct. October 2021, 12 (20): 9563–9582. PMID 34533553. doi:10.1039/d1fo02093e.
Chua SS, Benrimoj SI, Triggs EJ. Pharmacokinetics of non-prescription sympathomimetic agents. Biopharm Drug Dispos. 1989, 10 (1): 1–14. PMID 2647163. doi:10.1002/bdd.2510100102.
Abourashed EA, El-Alfy AT, Khan IA, Walker L. Ephedra in perspective—a current review. Phytotherapy Research. August 2003, 17 (7): 703–712. PMID 12916063. S2CID 41083359. doi:10.1002/ptr.1337.
Drew CD, Knight GT, Hughes DT, Bush M. Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. British Journal of Clinical Pharmacology. September 1978, 6 (3): 221–5. PMC 1429447 . PMID 687500. doi:10.1111/j.1365-2125.1978.tb04588.x.
Higashida K, Yamada M, Shimohata T. Quick and long-lasting responsiveness by ephedrine in an adult woman with congenital myasthenic syndrome associated with a novel COLQ mutation. (2928). Neurology. 2021-04-13, 96 (15 Supplement) [2024-09-18]. ISSN 0028-3878. S2CID 266124150. doi:10.1212/WNL.96.15_supplement.2928. （原始内容存档于2022-11-23）.
Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. March 2003, 289 (12): 1537–45. PMID 12672771. doi:10.1001/jama.289.12.1470.
Dwyer JT, Allison DB, Coates PM. Dietary supplements in weight reduction. Journal of the American Dietetic Association. May 2005, 105 (5 Suppl 1): S80–6 [2024-09-18]. PMID 15867902. doi:10.1016/j.jada.2005.02.028. （原始内容存档于2020-08-09）.
Magkos F, Kavouras SA. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Medicine. 2004, 34 (13): 871–89. PMID 15487903. S2CID 1966020. doi:10.2165/00007256-200434130-00002.
Yoo HJ, Yoon HY, Yee J, Gwak HS. Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmaceuticals. November 2021, 14 (11): 1198. PMC 8618781 . PMID 34832979. doi:10.3390/ph14111198 .
Palamar J. How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy. January 2011, 99 (1): 1–9. PMID 20685002. doi:10.1016/j.healthpol.2010.07.007.
Edinoff, Amber N.; Swinford, Connor R. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors 10 (4): 39576. 2022-011-03 [2024-09-02]. doi:10.52965/001c.39576. （原始内容存档于2024-07-23）. 已忽略文本“journalHealth Psychology Research” (帮助); 请检查|date=中的日期值 (帮助)
Docherty JR. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Br J Pharmacol. June 2008, 154 (3): 606–622. PMC 2439527 . PMID 18500382. doi:10.1038/bjp.2008.124.
Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, et al. Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes. The Journal of Pharmacology and Experimental Therapeutics. July 2007, 322 (1): 214–221. PMID 17405867. S2CID 86429875. doi:10.1124/jpet.107.120709.
Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, et al. The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release?. Anesthesia and Analgesia. November 2003, 97 (5): 1239–1245. PMID 14570629. doi:10.1213/01.ANE.0000092917.96558.3C .
Munhall AC, Johnson SW. Dopamine-mediated actions of ephedrine in the rat substantia nigra. Brain Research. January 2006, 1069 (1): 96–103. PMID 16386715. S2CID 40626692. doi:10.1016/j.brainres.2005.11.044.
Schier JG, Traub SJ, Hoffman RS, Nelson LS. Ephedrine-induced cardiac ischemia: exposure confirmed with a serum level. Journal of Toxicology. Clinical Toxicology. 2003, 41 (6): 849–53. PMID 14677795. S2CID 23359388. doi:10.1081/clt-120025350.
Lieberman HR. The effects of ginseng, ephedrine, and caffeine on cognitive performance, mood and energy. Nutr Rev. April 2001, 59 (4): 91–102. PMID 11368507. doi:10.1111/j.1753-4887.2001.tb06995.x.
Magkos F, Kavouras SA. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Med. 2004, 34 (13): 871–889. PMID 15487903. doi:10.2165/00007256-200434130-00002.
Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. European Annals of Otorhinolaryngology, Head and Neck Diseases. February 2015, 132 (1): 31–4. PMID 25532441. doi:10.1016/j.anorl.2014.11.001 .
Zhu, Binling; Conlan, Xavier. Case studies on illegal production of ephedrine/pseudoephedrine within Fujian China. Forensic Science International. July 2020, 312 [2024-09-02]. doi:10.1016/j.forsciint.2020.110326.
Hertweck C, Jarvis AP, Xiang L, Moore BS, Oldham NJ. A mechanism of benzoic acid biosynthesis in plants and bacteria that mirrors fatty acid beta-oxidation. ChemBioChem. October 2001, 2 (10): 784–6. PMID 11948863. S2CID 28159196. doi:10.1002/1439-7633(20011001)2:10<784::AID-CBIC784>3.0.CO;2-K.
Grue-Sorensen G, Spenser ID. Biosynthesis of ephedrine. Journal of the American Chemical Society. May 1, 1988, 110 (11): 3714–3715. ISSN 0002-7863. doi:10.1021/ja00219a086.
Yamasaki K, Tamaki T, Uzawa S, Sankawa U, Shibata S. Participation of C6-C1 unit in the biosynthesis of ephedrine in Ephedra. Phytochemistry. 1973, 12 (12): 2877–2882. Bibcode:1973PChem..12.2877Y. doi:10.1016/0031-9422(73)80499-6.

drugbank.com

go.drugbank.com

Ephedrine: Uses, Interactions, Mechanism of Action. DrugBank Online. 2016-04-29 [2024-07-14]. （原始内容存档于2024-09-14）.

drugfreesport.com

Sport Drug Testing – Drug Programs & Policy – Athletics. [2011-03-21]. （原始内容存档于2011-02-10）.

drugs.com

Ephedrine. The American Society of Health-System Pharmacists. [2017-09-08]. （原始内容存档于2017-09-09）.
Ephedrine Pregnancy and Breastfeeding Warnings. [2017-10-08]. （原始内容存档于2017-08-05）.

ephedrinehydrochloride.com

Nutraceutical Corporation; Solaray, Inc., Plaintiffs-appellees, v. Andrew Von Eschenbach, Acting Commissioner, U.S. Food and Drug Administration; United States Food and Drug Administration; Michael O. Leavitt, Secretary of the Department of Health and Human Services; Department of Health and Human Services; United States of America (PDF). [2010-07-01]. （原始内容 (PDF)存档于2011-07-10）. Defendants-appellants, 459 F.3d 1033 (10th Cir. 2006)

fda.gov

accessdata.fda.gov

Drugs@FDA: FDA-Approved Drugs. accessdata.fda.gov. Food and Drug Administration. [2024-07-14]. （原始内容存档于2017-11-02）.

federalregister.gov

ecfr.federalregister.gov

Title 21: Food And Drugs Part 341—Cold, Cough, Allergy, Bronchodilator, And Antiasthmatic Drug Products For Over-The-Counter Human Use. Electronic Code of Federal Regulations. [2020-10-08]. （原始内容存档于2022-04-06）.

handle.net

hdl.handle.net

World Health Organization. World Health Organization model list of essential medicines: 22nd list (2021). Geneva: World Health Organization. 2021. hdl:10665/345533 . WHO/MHP/HPS/EML/2021.02.

harvard.edu

ui.adsabs.harvard.edu

Yamasaki K, Tamaki T, Uzawa S, Sankawa U, Shibata S. Participation of C6-C1 unit in the biosynthesis of ephedrine in Ephedra. Phytochemistry. 1973, 12 (12): 2877–2882. Bibcode:1973PChem..12.2877Y. doi:10.1016/0031-9422(73)80499-6.

hc-sc.gc.ca

Health Canada requests recall of certain products containing Ephedra/ephedrine. Health Canada. January 9, 2002 [July 7, 2009]. （原始内容存档于2007-02-06）.

in.gov.br

Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-15]. （原始内容存档于2023-08-03）（巴西葡萄牙语）.

incb.org

Microsoft Word – RedListE2007.doc 互联网档案馆的存檔，存档日期2008-02-27.

justice.gc.ca

laws-lois.justice.gc.ca

Legislative Services Branch. Consolidated federal laws of canada, Controlled Drugs and Substances Act. laws-lois.justice.gc.ca. 2021-03-18 [2021-07-30]. （原始内容存档于2021-07-30）.

medicines.org.uk

Ephedrine Hydrochloride 15mg Tablets Summary of Product Characteristics (SmPC). emc. [8 October 2020]. （原始内容存档于2021-05-09）.
Ephedrine Nasal Drops 1.0% Summary of Product Characteristics (SmPC). emc. 11 March 2015 [2020-10-08]. （原始内容存档于24 October 2020）.

merckmanuals.com

EPHEDrine. Merck Manuals. January 2010. （原始内容存档于2011-03-24）.

mhmedical.com

accessanesthesiology.mhmedical.com

Butterworth IV JF, Mackey DC, Wasnick JD. Chapter 14. Adrenergic Agonists & Antagonists.. Morgan & Mikhail's Clinical Anesthesiology 7th. McGraw-Hill Education. 2022 [2024-09-18]. ISBN 978-1-260-47379-7. （原始内容存档于2024-12-05）.

neurology.org

n.neurology.org

Higashida K, Yamada M, Shimohata T. Quick and long-lasting responsiveness by ephedrine in an adult woman with congenital myasthenic syndrome associated with a novel COLQ mutation. (2928). Neurology. 2021-04-13, 96 (15 Supplement) [2024-09-18]. ISSN 0028-3878. S2CID 266124150. doi:10.1212/WNL.96.15_supplement.2928. （原始内容存档于2022-11-23）.

nih.gov

ncbi.nlm.nih.gov

Volpp M, Holzgrabe U. Determination of plasma protein binding for sympathomimetic drugs by means of ultrafiltration. Eur J Pharm Sci. January 2019, 127: 175–184. PMID 30391401. doi:10.1016/j.ejps.2018.10.027.
Gad MZ, Azab SS, Khattab AR, Farag MA. Over a century since ephedrine discovery: an updated revisit to its pharmacological aspects, functionality and toxicity in comparison to its herbal extracts. Food Funct. October 2021, 12 (20): 9563–9582. PMID 34533553. doi:10.1039/d1fo02093e.
Chua SS, Benrimoj SI, Triggs EJ. Pharmacokinetics of non-prescription sympathomimetic agents. Biopharm Drug Dispos. 1989, 10 (1): 1–14. PMID 2647163. doi:10.1002/bdd.2510100102.
Abourashed EA, El-Alfy AT, Khan IA, Walker L. Ephedra in perspective—a current review. Phytotherapy Research. August 2003, 17 (7): 703–712. PMID 12916063. S2CID 41083359. doi:10.1002/ptr.1337.
Drew CD, Knight GT, Hughes DT, Bush M. Comparison of the effects of D-(-)-ephedrine and L-(+)-pseudoephedrine on the cardiovascular and respiratory systems in man. British Journal of Clinical Pharmacology. September 1978, 6 (3): 221–5. PMC 1429447 . PMID 687500. doi:10.1111/j.1365-2125.1978.tb04588.x.
Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, et al. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA. March 2003, 289 (12): 1537–45. PMID 12672771. doi:10.1001/jama.289.12.1470.
Dwyer JT, Allison DB, Coates PM. Dietary supplements in weight reduction. Journal of the American Dietetic Association. May 2005, 105 (5 Suppl 1): S80–6 [2024-09-18]. PMID 15867902. doi:10.1016/j.jada.2005.02.028. （原始内容存档于2020-08-09）.
Magkos F, Kavouras SA. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Medicine. 2004, 34 (13): 871–89. PMID 15487903. S2CID 1966020. doi:10.2165/00007256-200434130-00002.
Yoo HJ, Yoon HY, Yee J, Gwak HS. Effects of Ephedrine-Containing Products on Weight Loss and Lipid Profiles: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Pharmaceuticals. November 2021, 14 (11): 1198. PMC 8618781 . PMID 34832979. doi:10.3390/ph14111198 .
Palamar J. How ephedrine escaped regulation in the United States: a historical review of misuse and associated policy. Health Policy. January 2011, 99 (1): 1–9. PMID 20685002. doi:10.1016/j.healthpol.2010.07.007.
Alec K. Statler; Christopher V. Maani; Arpan Kohli. Ephedrine. StatPearls [Internet]. [2024-09-02]. （原始内容存档于2023-03-06）.
Edinoff, Amber N.; Swinford, Connor R. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors 10 (4): 39576. 2022-011-03 [2024-09-02]. doi:10.52965/001c.39576. （原始内容存档于2024-07-23）. 已忽略文本“journalHealth Psychology Research” (帮助); 请检查|date=中的日期值 (帮助)
Docherty JR. Pharmacology of stimulants prohibited by the World Anti-Doping Agency (WADA). Br J Pharmacol. June 2008, 154 (3): 606–622. PMC 2439527 . PMID 18500382. doi:10.1038/bjp.2008.124.
Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, et al. Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes. The Journal of Pharmacology and Experimental Therapeutics. July 2007, 322 (1): 214–221. PMID 17405867. S2CID 86429875. doi:10.1124/jpet.107.120709.
Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, et al. The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release?. Anesthesia and Analgesia. November 2003, 97 (5): 1239–1245. PMID 14570629. doi:10.1213/01.ANE.0000092917.96558.3C .
Munhall AC, Johnson SW. Dopamine-mediated actions of ephedrine in the rat substantia nigra. Brain Research. January 2006, 1069 (1): 96–103. PMID 16386715. S2CID 40626692. doi:10.1016/j.brainres.2005.11.044.
Schier JG, Traub SJ, Hoffman RS, Nelson LS. Ephedrine-induced cardiac ischemia: exposure confirmed with a serum level. Journal of Toxicology. Clinical Toxicology. 2003, 41 (6): 849–53. PMID 14677795. S2CID 23359388. doi:10.1081/clt-120025350.
Lieberman HR. The effects of ginseng, ephedrine, and caffeine on cognitive performance, mood and energy. Nutr Rev. April 2001, 59 (4): 91–102. PMID 11368507. doi:10.1111/j.1753-4887.2001.tb06995.x.
Magkos F, Kavouras SA. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Med. 2004, 34 (13): 871–889. PMID 15487903. doi:10.2165/00007256-200434130-00002.
Graham TE. Caffeine, coffee and ephedrine: impact on exercise performance and metabolism. Can J Appl Physiol. 2001,. 26 Suppl: S103–S119. PMID 11897887.
Laccourreye O, Werner A, Giroud JP, Couloigner V, Bonfils P, Bondon-Guitton E. Benefits, limits and danger of ephedrine and pseudoephedrine as nasal decongestants. European Annals of Otorhinolaryngology, Head and Neck Diseases. February 2015, 132 (1): 31–4. PMID 25532441. doi:10.1016/j.anorl.2014.11.001 .
Hertweck C, Jarvis AP, Xiang L, Moore BS, Oldham NJ. A mechanism of benzoic acid biosynthesis in plants and bacteria that mirrors fatty acid beta-oxidation. ChemBioChem. October 2001, 2 (10): 784–6. PMID 11948863. S2CID 28159196. doi:10.1002/1439-7633(20011001)2:10<784::AID-CBIC784>3.0.CO;2-K.

dailymed.nlm.nih.gov

Akovaz- ephedrine sulfate injection. DailyMed. 16 April 2020 [8 October 2020]. （原始内容存档于2020-09-26）.
Search Results for ephedrine. DailyMed. [2024-07-14]. （原始内容存档于2024-12-05）.

pubchem.ncbi.nlm.nih.gov

Ephedrine. PubChem. [2024-08-30]. （原始内容存档于2024-12-03）.

sciencedirect.com

Zhu, Binling; Conlan, Xavier. Case studies on illegal production of ephedrine/pseudoephedrine within Fujian China. Forensic Science International. July 2020, 312 [2024-09-02]. doi:10.1016/j.forsciint.2020.110326.

semanticscholar.org

api.semanticscholar.org

Abourashed EA, El-Alfy AT, Khan IA, Walker L. Ephedra in perspective—a current review. Phytotherapy Research. August 2003, 17 (7): 703–712. PMID 12916063. S2CID 41083359. doi:10.1002/ptr.1337.
Higashida K, Yamada M, Shimohata T. Quick and long-lasting responsiveness by ephedrine in an adult woman with congenital myasthenic syndrome associated with a novel COLQ mutation. (2928). Neurology. 2021-04-13, 96 (15 Supplement) [2024-09-18]. ISSN 0028-3878. S2CID 266124150. doi:10.1212/WNL.96.15_supplement.2928. （原始内容存档于2022-11-23）.
Magkos F, Kavouras SA. Caffeine and ephedrine: physiological, metabolic and performance-enhancing effects. Sports Medicine. 2004, 34 (13): 871–89. PMID 15487903. S2CID 1966020. doi:10.2165/00007256-200434130-00002.
Ma G, Bavadekar SA, Davis YM, Lalchandani SG, Nagmani R, Schaneberg BT, et al. Pharmacological effects of ephedrine alkaloids on human alpha(1)- and alpha(2)-adrenergic receptor subtypes. The Journal of Pharmacology and Experimental Therapeutics. July 2007, 322 (1): 214–221. PMID 17405867. S2CID 86429875. doi:10.1124/jpet.107.120709.
Munhall AC, Johnson SW. Dopamine-mediated actions of ephedrine in the rat substantia nigra. Brain Research. January 2006, 1069 (1): 96–103. PMID 16386715. S2CID 40626692. doi:10.1016/j.brainres.2005.11.044.
Schier JG, Traub SJ, Hoffman RS, Nelson LS. Ephedrine-induced cardiac ischemia: exposure confirmed with a serum level. Journal of Toxicology. Clinical Toxicology. 2003, 41 (6): 849–53. PMID 14677795. S2CID 23359388. doi:10.1081/clt-120025350.
Hertweck C, Jarvis AP, Xiang L, Moore BS, Oldham NJ. A mechanism of benzoic acid biosynthesis in plants and bacteria that mirrors fatty acid beta-oxidation. ChemBioChem. October 2001, 2 (10): 784–6. PMID 11948863. S2CID 28159196. doi:10.1002/1439-7633(20011001)2:10<784::AID-CBIC784>3.0.CO;2-K.

wada-ama.org

list.wada-ama.org

S6. Stimulants | List of Prohibited Substances and Methods. [2015-10-19]. （原始内容存档于2015-10-23）.

wada-ama.org

WADA. The World Anti-Doping Code, World Anti-Doping Agency, Montreal, Canada, 2010. url 互联网档案馆的存檔，存档日期2013-09-11.

web.archive.org

Ephedrine Hydrochloride 15mg Tablets Summary of Product Characteristics (SmPC). emc. [8 October 2020]. （原始内容存档于2021-05-09）.
Ephedrine Nasal Drops 1.0% Summary of Product Characteristics (SmPC). emc. 11 March 2015 [2020-10-08]. （原始内容存档于24 October 2020）.
Akovaz- ephedrine sulfate injection. DailyMed. 16 April 2020 [8 October 2020]. （原始内容存档于2020-09-26）.
Title 21: Food And Drugs Part 341—Cold, Cough, Allergy, Bronchodilator, And Antiasthmatic Drug Products For Over-The-Counter Human Use. Electronic Code of Federal Regulations. [2020-10-08]. （原始内容存档于2022-04-06）.
Ephedrine: Uses, Interactions, Mechanism of Action. DrugBank Online. 2016-04-29 [2024-07-14]. （原始内容存档于2024-09-14）.
Ephedrine. The American Society of Health-System Pharmacists. [2017-09-08]. （原始内容存档于2017-09-09）.
Anvisa. RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control]. Diário Oficial da União. 2023-03-31 (2023-04-04) [2023-08-15]. （原始内容存档于2023-08-03）（巴西葡萄牙语）.
Briggs GG, Freeman RK, Yaffe SJ. Drugs in pregnancy and lactation : a reference guide to fetal and neonatal risk 9th. Philadelphia: Lippincott Williams & Wilkins. 2011: 495. ISBN 9781608317080. （原始内容存档于2017-09-08）.
Ephedrine Pregnancy and Breastfeeding Warnings. [2017-10-08]. （原始内容存档于2017-08-05）.
Ephedrine. PubChem. [2024-08-30]. （原始内容存档于2024-12-03）.
Soni MG, Shelke K, Amin R, Talati. A Lessons from the Use of Ephedra Products as a Dietary Supplement. Bagchi D, Preuss HG (编). Obesity epidemiology, pathophysiology, and prevention 2nd. Boca Raton, Florida: CRC Press. 2013: 692. ISBN 9781439854266. （原始内容存档于2017-09-08）.
Butterworth IV JF, Mackey DC, Wasnick JD. Chapter 14. Adrenergic Agonists & Antagonists.. Morgan & Mikhail's Clinical Anesthesiology 7th. McGraw-Hill Education. 2022 [2024-09-18]. ISBN 978-1-260-47379-7. （原始内容存档于2024-12-05）.
Higashida K, Yamada M, Shimohata T. Quick and long-lasting responsiveness by ephedrine in an adult woman with congenital myasthenic syndrome associated with a novel COLQ mutation. (2928). Neurology. 2021-04-13, 96 (15 Supplement) [2024-09-18]. ISSN 0028-3878. S2CID 266124150. doi:10.1212/WNL.96.15_supplement.2928. （原始内容存档于2022-11-23）.
Dwyer JT, Allison DB, Coates PM. Dietary supplements in weight reduction. Journal of the American Dietetic Association. May 2005, 105 (5 Suppl 1): S80–6 [2024-09-18]. PMID 15867902. doi:10.1016/j.jada.2005.02.028. （原始内容存档于2020-08-09）.
Bray GA, Bouchard C. Handbook of obesity. CRC Press. 2004: 494–496. ISBN 978-0-8247-4773-2. （原始内容存档于2014-06-26）.
Drugs@FDA: FDA-Approved Drugs. accessdata.fda.gov. Food and Drug Administration. [2024-07-14]. （原始内容存档于2017-11-02）.
Search Results for ephedrine. DailyMed. [2024-07-14]. （原始内容存档于2024-12-05）.
Alec K. Statler; Christopher V. Maani; Arpan Kohli. Ephedrine. StatPearls [Internet]. [2024-09-02]. （原始内容存档于2023-03-06）.
Edinoff, Amber N.; Swinford, Connor R. Clinically Relevant Drug Interactions with Monoamine Oxidase Inhibitors 10 (4): 39576. 2022-011-03 [2024-09-02]. doi:10.52965/001c.39576. （原始内容存档于2024-07-23）. 已忽略文本“journalHealth Psychology Research” (帮助); 请检查|date=中的日期值 (帮助)
EPHEDrine. Merck Manuals. January 2010. （原始内容存档于2011-03-24）.
S6. Stimulants | List of Prohibited Substances and Methods. [2015-10-19]. （原始内容存档于2015-10-23）.
WADA. The World Anti-Doping Code, World Anti-Doping Agency, Montreal, Canada, 2010. url 互联网档案馆的存檔，存档日期2013-09-11.
Microsoft Word – RedListE2007.doc 互联网档案馆的存檔，存档日期2008-02-27.
Health Canada requests recall of certain products containing Ephedra/ephedrine. Health Canada. January 9, 2002 [July 7, 2009]. （原始内容存档于2007-02-06）.
Legislative Services Branch. Consolidated federal laws of canada, Controlled Drugs and Substances Act. laws-lois.justice.gc.ca. 2021-03-18 [2021-07-30]. （原始内容存档于2021-07-30）.
Federal Register: June 4, 1997 (Volume 62, Number 107): Dietary Supplements Containing Ephedrine Alkaloids; Proposed Rule
Federal Register: April 3, 2000 (Volume 65, Number 64): Dietary Supplements Containing Ephedrine Alkaloids; Withdrawal in Part
Federal Register: February 11, 2004 (Volume 69, Number 28): Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk; Final Rule
Nutraceutical Corporation; Solaray, Inc., Plaintiffs-appellees, v. Andrew Von Eschenbach, Acting Commissioner, U.S. Food and Drug Administration; United States Food and Drug Administration; Michael O. Leavitt, Secretary of the Department of Health and Human Services; Department of Health and Human Services; United States of America (PDF). [2010-07-01]. （原始内容 (PDF)存档于2011-07-10）. Defendants-appellants, 459 F.3d 1033 (10th Cir. 2006)
Nutraceutical Corporation; Solaray, Inc. Plaintiffs-Appellees vs. Andrew Von Eschenbach, Acting Commissioner, US.. Food and Drug Administration; United States Food and Drug Administration; Michael O. Leavitt, Secretary of the Department of Health and Human Services; Department of Health and Human Services; United States of America, We find that the FDA correctly followed the congressional directive to analyze the risks and benefits of EDS in determining that there is no dosage level of EDS acceptable for the market. (United States Court of Appeals Tenth Circuit 2006-08-17).^{[失效連結]}
Sport Drug Testing – Drug Programs & Policy – Athletics. [2011-03-21]. （原始内容存档于2011-02-10）.
Rescheduling of Medicines that Contain Ephedrine. [2009-04-18]. （原始内容存档于2009-06-28）.
Verordnung zur Neuordnung der Verschreibungspflicht von Arzneimitteln (AMVVNV). 互联网档案馆的存檔，存档日期2014-05-17. V. v. 21. Dezember 2005 BGBl. I S. 3632; Geltung ab 1. Januar 2006.
Long C. Chinese medicine's great waste of resources. 2007-01-15 [2016-05-09]. （原始内容存档于2016-05-30）.

worldcat.org

Higashida K, Yamada M, Shimohata T. Quick and long-lasting responsiveness by ephedrine in an adult woman with congenital myasthenic syndrome associated with a novel COLQ mutation. (2928). Neurology. 2021-04-13, 96 (15 Supplement) [2024-09-18]. ISSN 0028-3878. S2CID 266124150. doi:10.1212/WNL.96.15_supplement.2928. （原始内容存档于2022-11-23）.
Grue-Sorensen G, Spenser ID. Biosynthesis of ephedrine. Journal of the American Chemical Society. May 1, 1988, 110 (11): 3714–3715. ISSN 0002-7863. doi:10.1021/ja00219a086.

zenodo.org

Dwyer JT, Allison DB, Coates PM. Dietary supplements in weight reduction. Journal of the American Dietetic Association. May 2005, 105 (5 Suppl 1): S80–6 [2024-09-18]. PMID 15867902. doi:10.1016/j.jada.2005.02.028. （原始内容存档于2020-08-09）.